BMEA

BMEA

Biomea Fusion Inc

Rev โ€”top 1%5Y
Hold

Biomea Fusion develops oral drugs targeting diabetes and obesity. Its lead candidates, icovamenib and BMF-650, are in clinical trials aimed at restoring insulin production and managing weight, addressing significant metabolic health challenges.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$109today

Score Overview

1 Year
Scoreโ€”
Net Growth60.82%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth41.26%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth41.26%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Biomea Fusion Inc fundamental performance

Across Biomea Fusion Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 41M to -$ 61M. Revenue increased in 0% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.28โ€”
1 Year2025-08-12
$ 1.65-22.42%
5 Years2021-08-12
$ 11.73-89.09%
All Time2021-04-16
$ 18.60-93.12%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 24M$ 34M
2025$ 0.00-$ 61M$ 55M
2024$ 0.00-$ 138M$ 58M
2023$ 0.00-$ 117M$ 176M
2022$ 0.00-$ 80M$ 113M
IPO2021$ 0.00-$ 41M$ 173M

Explore beyond BMEA

You're looking at Biomea Fusion Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies